Kinnate slashes workforce by 70%, shelves three drug programs

Layoff Notice

WendellandCarolyn/iStock via Getty Images

Kinnate Biopharma (NASDAQ:KNTE) said late Monday that it was slashing its workforce by 70% as part of a reprioritization of its drug development programs.

The biotech company said the cuts will leave it with 28 full-time employees and also result


Business Asia
the authorBusiness Asia

Leave a Reply